CUSTOM DERMATOLOGY SEARCH:
The Thalidomide Chronology
Introduced in the late 1950’s
Worldwide ban in 1961
From the ban until now
1988 – WHO recommend
Late 1997 – first US approval nears
Use of thalidomide for ENL
The WHO has stated that thalidomide is a treatment of choice for severe ENL and now the FDA has decided that the benefits of treatment with thalidomide outweigh the risks involved. ENL can be life threatening and may cause permanent nerve paralysis and disfigurement. Previously available treatments for severe ENL, corticosteroids and clofazimine are not very effective. Mild ENL has been successfully treated with aspirin, indomethacin, chloroquine or colchicine.
Other uses of thalidomide
More than 20 clinical trials are underway and the drug is also supplied on an emergency use basis or investigator IND basis for over 30 conditions. Currently the dermatologic conditions include Behcet’s disease, prurigo nodularis, discoid lupus erythematosus, pyoderma gangrenosum, erythema multiforme, Jessner’s lymphatic infiltration, pompholyx, scleroderma, urticaria, bullous pemphigoid and cutaneous sarcoidosis.3
Mechanism of action
The mechanism by which thalidomide reduces the elevated levels of tumor necrosis factor-alpha (TNF-α) associated with ENL is yet to be understood.4 Thalidomide has other immunopharmacologic actions which are under investigation.4
Restricted distribution Celgene designed and has submitted a restricted distribution proposal ( System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) to the FDA. The objective of the S.T.E.P.S. program is to help insure that fetal exposure to thalidomide occurs with the lowest possible incidence. This comprehensive program will be directed to physicians, pharmacists, and patients, both male and female. It will require all physicians and pharmacies to register in order to prescribe or dispense Thalomid™ (thalidomide) and all patients to complete an informed consent process and participate in a mandatory and confidential surveillance registry.
Supply of thalidomide
Thalomid™ will possibly be available commercially in the first half of this year. The projected cost of a 50 mg capsule is US$6, meaning that daily treatment of ENL (100–200 mg per day) will cost approximately US$12–24. Patients will only get a 28 day supply; subsequent supply requires a new prescription.3
The most common adverse effects are drowsiness, rash and constipation.
Peripheral neuropathy occurs in less than 1% of ENL patients treated with thalidomide, despite long-term treatment, pre-existing neuropathies, or use in patients who are receiving other medications known to be associated with neuropathies.3 Neuropathy is more common (between 21% and 50%) in AIDS patients. The neuropathy generally occurs following chronic use over a period of months but reports following relatively short-term use also exist. In some cases, the nerve damage has proved irreversible even after treatment with the drug is discontinued. Individual susceptibilities, with possible genetic predisposition, seem to be more important than daily dose and duration of therapy.10 Patients should be examined for early signs of neuropathy at monthly intervals for the first three months.3 Symptoms of nerve damage include numbness, tingling or pain in the arms, hands, legs and feet. Patients should be warned of this side effect, and understand that they must stop thalidomide immediately if paresthesias develop.11 To detect asymptomatic neuropathy, consider measuring sensory nerve action potential (SNAP) at baseline and every six months. If symptoms develop, stop thalidomide immediately and only restart therapy if the neuropathy completely resolves.3
At the meeting of the FDA Advisory Committee, a spokesman for the 5,000 individuals with birth defects caused by thalidomide who are still living, was saddened at the prospect of potential approval but said that the group preferred regulation to unmonitored use of black market supplies. Celgene said that there have been no birth defects reported so far among the 5,000 ENL patients who have received thalidomide, either through clinical trials or on an emergency basis.
Molecular manipulation has uncovered other thalidomide-related compounds which inhibit TNF-α production more efficiently than thalidomide, and cause fewer side effects in animals.5 Celgene’s first compound entered Phase 1 clinical study in 1997.3 The goal, a non-teratogenic compound, with equal or greater immunomodulating potential than thalidomide, offers the exciting possibility of new and relatively safe compounds which may prove effective in treating diseases at present resistant to currently available therapies. Thalidomide itself has a range of interesting and potentially useful immunopharmacologic actions4 and after further study and sensible precautions as to its use, has a clear potential as a future immunomodulator.4
In this issue:
All content ©2004-2017 SkinTherapyLetter® |
Last modified: Friday, 11-Dec-2015 14:45:54 MST